A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04634552 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

510

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematological Malignancies

Interventions

DRUG: Talquetamab

Sponsor

Janssen Research & Development, LLC